The definitive benchmark for cell therapy dealmaking
Cell therapy partnering is driven by advanced and highly specialised therapeutic approaches, with deal structures reflecting complex development pathways, manufacturing requirements, and high-value innovation.
This report provides a comprehensive and structured analysis of 1080+ cell therapy collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how cell therapy deals are structured in practice, allowing you to:
- Benchmark comparable transactions with confidence
- Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
- Define realistic market parameters
- Clear insight into how deal terms vary by therapy type, development stage, and partner profile
- Support valuation and structuring decisions with evidence
- Ground internal discussions in real transaction data rather than assumptions
- Understand how leading companies approach dealmaking
- Visibility into partner behaviour and recurring deal structures across a technically complex and rapidly evolving therapeutic landscape
- Full visibility into deal structure and execution
- Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.
This includes:
- Rights granted and retained
- Development and commercialization responsibilities
- Financial structures and payment triggers
- Key contractual provisions and protections
- This level of transparency is critical to understanding how value, risk, and control are allocated within cell therapy partnerships, particularly in areas involving manufacturing scale-up, supply chain considerations, and regulatory complexity.
- Designed for real-world BD and strategy use
The report is widely used to:
- Structure and benchmark advanced therapy transactions
- Prepare for negotiations with well-defined market context
- Evaluate licensing, co-development, and platform partnerships
- Support internal strategy with robust, defensible data
- What's included
- 1080+ cell therapy collaboration and licensing deals
- Financial terms, including upfronts, milestones, and royalties where disclosed
- Fully searchable deal directory (by company, therapy type, and development stage)
- Direct access to SEC-filed agreements and source documents
- Analysis of deal trends, key transactions, and active dealmakers
- A trusted, evidence-based reference for cell therapy dealmaking
- Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cell therapy partnerships are structured, negotiated, and valued.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in cell therapy dealmaking
- 2.1. Introduction
- 2.2. Cell therapy deals over the years
- 2.3. Most active cell therapy dealmakers
- 2.4. Cell therapy deals by deal type
- 2.5. Cell therapy deals by therapy area
- 2.6. Cell therapy deals by industry sector
- 2.7. Deal terms for cell therapy deals
- 2.7.1 Cell therapy deals headline values
- 2.7.2 Cell therapy deal upfront payments
- 2.7.3 Cell therapy deal milestone payments
- 2.7.4 Cell therapy royalty rates
Chapter 3 - Leading cell therapy deals
- 3.1. Introduction
- 3.2. Top cell therapy deals by value
Chapter 4 - Most active cell therapy dealmakers
- 4.1. Introduction
- 4.2. Most active cell therapy dealmakers
- 4.3. Most active cell therapy deals company profiles
Chapter 5 - Cell therapy contracts dealmaking directory
- 5.1. Introduction
- 5.2. Cell therapy contracts dealmaking directory
Chapter 6 - Cell therapy dealmaking by technology type
- Deal directory
- Deal directory - Cell therapy deals by company A-Z
- Deal directory - Cell therapy deals by deal type
- Deal directory - Cell therapy deals by therapy area
- Deal type definitions
- About Biopharma Research Ltd
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
Table of figures
- Figure 1: Cell therapy deals since 2016
- Figure 2: Active cell therapy dealmaking activity since 2016
- Figure 3: Cell therapy deals by deal type since 2016
- Figure 4: Cell therapy deals by therapy area since 2016
- Figure 5: Cell therapy deals by industry sector since 2016
- Figure 6: Cell therapy deals with a headline value
- Figure 7: Cell therapy deals with an upfront value
- Figure 8: Cell therapy deals with a milestone value
- Figure 9: Cell therapy deals with a royalty rate value
- Figure 10: Top cell therapy deals by value since 2016
- Figure 11: Most active cell therapy dealmakers since 2016
- Figure 12: Cell therapy deals by technology type since 2016